Instil Bio (NASDAQ:TIL), a clinical-stage biopharmaceutical company, today reported its financial results for the fourth quarter and full year ended December 31, 2025, while outlining a transformative shift in its corporate strategy.
Following the recent discontinuation of its lead clinical program, the company is repositioning itself as an acquisition-focused entity, prioritizing external innovation to rebuild its therapeutic pipeline.
For the full year 2025, Instil Bio reported a net loss of $71.4 million, or $10.70 per share, representing a slight improvement from the $74.1 million net loss recorded in 2024.
The company’s total operating expenses for the year were $78.6 million, which included $24.7 million in research and development and $27.2 million in general and administrative costs.
Notably, the fiscal year was marked by $16.6 million in restructuring and impairment charges as the company aggressively streamlined its internal operations.
The most significant update involves the company's pipeline transition.
In January 2026, Instil’s subsidiary, Axion Bio, discontinued the clinical development of AXN-2510, a PD-L1xVEGF bispecific antibody, and terminated its collaboration agreement with ImmuneOnco.
With no active internal development programs remaining, Instil is now dedicated to a "disciplined capital deployment" strategy.
This involves seeking high-quality acquisitions and in-licensing opportunities across multiple therapeutic areas to drive long-term shareholder value.
Financially, Instil Bio remains well-capitalized to execute this new direction.
The company ended 2025 with $76.3 million in cash, cash equivalents, and marketable securities.
Management expects this liquidity to fund the current operating plan beyond 2027, providing a multi-year window to identify and secure new clinical-stage assets.